BCL-2 Family Proteins as Therapeutic Targets in Multiple Myeloma - Episode 8

Other Venetoclax-based Combination Regimens Being Evaluated in Multiple Myeloma

,

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Jonathan Kaufman, MD, describes clinical trials looking at venetoclax resistance, including the CANOVA study.